文献速递核素与放射性配体治疗

177Lu-Lu-DOTA-TATE肽受体放射性核素治疗15例进展性难治性脑膜瘤的疗效与安全性

Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-12-01

该研究回顾性分析了2000至2020年间在本中心接受[177Lu]Lu-DOTA-TATE治疗的15例进展性难治性脑膜瘤患者,所有患者均已接受外照射放疗,14例曾接受手术。治疗后6例(40%)达疾病稳定,中位无进展生存期7.8个月,6个月无进展生存率60%;中位总生存期13.6个月,12个月总生存率60%。治疗后肿瘤生长率较治疗前下降。

要点

  • 15例进展性难治性脑膜瘤患者接受[177Lu]Lu-DOTA-TATE治疗,6例(40%)达疾病稳定。
  • 中位无进展生存期7.8个月,6个月无进展生存率60%。
  • 中位总生存期13.6个月,12个月总生存率60%。

核心结论

  • 在手术和放疗选择已耗竭且疾病进展的脑膜瘤患者队列中,肽受体放射性核素治疗(PRRT)显示出控制肿瘤生长的作用。

研究设计与样本

  • 回顾性分析2000至2020年间在本中心接受[177Lu]Lu-DOTA-TATE治疗的所有脑膜瘤患者,共15例。
  • 给药活度为7.5-29.6 GBq。
  • 所有患者PRRT前均接受过外照射放疗,14例曾接受手术;WHO分级包括1级(n=3)、2级(n=5)、3级(n=6)。
  • 主要结局为按RANO二维和体积标准的缓解及无进展生存期(PFS);总生存期(OS)和肿瘤生长率(TGR)为次要终点。
  • TGR按每月表面积或体积的百分比变化计算。

主要发现

  • PRRT后6例(40%)患者达疾病稳定。
  • 中位PFS为7.8个月,6个月PFS率60%;中位OS为13.6个月,12个月OS率60%。
  • PRRT前所有患者均为进展性疾病,平均TGR为表面积每月增加4.6%、体积每月增加14.8%。
  • PRRT后TGR降至表面积每月3.1%(p=0.016)、体积每月5.0%(p=0.013)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is no evidence-based systemic therapy for patients with progressive meningiomas for whom surgery or external radiotherapy is no longer an option. In this study, the efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with progressive, treatment-refractory meningiomas were evaluated. METHODS: Retrospective analysis of all meningioma patients treated with [177Lu]Lu-DOTA-TATE from 2000 to 2020 in our centre. Primary outcomes were response according to RANO bidimensional and volumetric criteria and progression-free survival (PFS). Overall survival (OS) and tumour growth rate (TGR) were secondary endpoints. TGR was calculated as the percentage change in surface or volume per month. RESULTS: Fifteen meningioma patients received [177Lu]Lu-DOTA-TATE (7.5-29.6 GBq). Prior to PRRT, all patients had received external radiotherapy, and 14 patients had undergone surgery. All WHO grades were included WHO 1 (n=3), WHO 2 (n=5), and WHO 3 (n=6). After PRRT, stable disease was observed in six (40%) patients. The median PFS was 7.8 months with a 6-month PFS rate of 60%. The median OS was 13.6 months with a 12-month OS rate of 60%. All patients had progressive disease prior to PRRT, with an average TGR of 4.6% increase in surface and 14.8% increase in volume per month. After PRRT, TGR declined to 3.1% in surface (p=0.016) and 5.0% in volume (p=0.013) per month. CONCLUSION: In this cohort of meningioma patients with exhaustion of surgical and radiotherapeutic options and progressive disease, it was shown that PRRT plays a role in controlling tumour growth.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Minczeles NS, Bos EM, de Leeuw RC, et al. Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. Eur J Nucl Med Mol Imaging. 2022. PMID: 36454268. doi:10.1007/s00259-022-06044-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。